OBJECTIVES: With comparable baseline performance on executive functions (EF) and memory between Alzheimer's disease (AD) and behavioral-variant frontotemporal dementia (bvFTD), it is currently unclear if both diseases can be distinguished longitudinally on these measures reliably. METHODS: A total of 111 participants (33 AD, 31 bvFTD, and 47 controls) were followed-up annually over a 4-year period and tested on measures of EF, memory, and orientation. Linear mixed-effect models were constructed using disease severity as a nuisance variable to examine profiles of neuropsychological performance decline. RESULTS: At baseline, overlap in terms of cognitive impairment between bvFTD and AD on multiple EF, memory, and orientation measures was present. Longitudinally, only disinhibition (Hayling total errors) appeared sensitive to discriminating AD from bvFTD; however, only after the first annual follow-up. Subgroup analyses on smaller samples revealed comparable profiles on EF tasks at baseline and over time between bvFTD and AD who presented with impaired EF at presentation, and on memory and orientation tasks between AD and bvFTD who presented with severe amnesia. CONCLUSIONS: Our results replicate previous findings showing only moderate discriminability between AD and bvFTD at clinical presentation on EF and memory measures. More importantly, we also show that longitudinal trajectories strongly overlap for both dementias on these measures. Disinhibition emerged as the sole measure that in the long run was significantly more impaired in bvFTD. Future studies should use tests designed to target cortical regions that are specifically impaired in bvFTD, such as the ventromedial prefrontal cortex, to improve the accurate discrimination of these diseases. (JINS, 2017, 23, 34-43).
OBJECTIVES: With comparable baseline performance on executive functions (EF) and memory between Alzheimer's disease (AD) and behavioral-variant frontotemporal dementia (bvFTD), it is currently unclear if both diseases can be distinguished longitudinally on these measures reliably. METHODS: A total of 111 participants (33 AD, 31 bvFTD, and 47 controls) were followed-up annually over a 4-year period and tested on measures of EF, memory, and orientation. Linear mixed-effect models were constructed using disease severity as a nuisance variable to examine profiles of neuropsychological performance decline. RESULTS: At baseline, overlap in terms of cognitive impairment between bvFTD and AD on multiple EF, memory, and orientation measures was present. Longitudinally, only disinhibition (Hayling total errors) appeared sensitive to discriminating AD from bvFTD; however, only after the first annual follow-up. Subgroup analyses on smaller samples revealed comparable profiles on EF tasks at baseline and over time between bvFTD and AD who presented with impaired EF at presentation, and on memory and orientation tasks between AD and bvFTD who presented with severe amnesia. CONCLUSIONS: Our results replicate previous findings showing only moderate discriminability between AD and bvFTD at clinical presentation on EF and memory measures. More importantly, we also show that longitudinal trajectories strongly overlap for both dementias on these measures. Disinhibition emerged as the sole measure that in the long run was significantly more impaired in bvFTD. Future studies should use tests designed to target cortical regions that are specifically impaired in bvFTD, such as the ventromedial prefrontal cortex, to improve the accurate discrimination of these diseases. (JINS, 2017, 23, 34-43).
Authors: Daniel E Gustavson; Chandra A Reynolds; Timothy J Hohman; Angela L Jefferson; Jeremy A Elman; Matthew S Panizzon; Michael C Neale; Mark W Logue; Michael J Lyons; Carol E Franz; William S Kremen Journal: J Int Neuropsychol Soc Date: 2022-02-21 Impact factor: 3.114
Authors: Jeffrey S Phillips; Fulvio Da Re; David J Irwin; Corey T McMillan; Sanjeev N Vaishnavi; Sharon X Xie; Edward B Lee; Philip A Cook; James C Gee; Leslie M Shaw; John Q Trojanowski; David A Wolk; Murray Grossman Journal: Brain Date: 2019-06-01 Impact factor: 13.501
Authors: Adam M Staffaroni; Peter A Ljubenkov; John Kornak; Yann Cobigo; Samir Datta; Gabe Marx; Samantha M Walters; Kevin Chiang; Nick Olney; Fanny M Elahi; David S Knopman; Bradford C Dickerson; Bradley F Boeve; Maria Luisa Gorno-Tempini; Salvatore Spina; Lea T Grinberg; William W Seeley; Bruce L Miller; Joel H Kramer; Adam L Boxer; Howard J Rosen Journal: Brain Date: 2019-02-01 Impact factor: 13.501
Authors: Daniel E Gustavson; Amy J Jak; Jeremy A Elman; Matthew S Panizzon; Carol E Franz; Katherine A Gifford; Chandra A Reynolds; Rosemary Toomey; Michael J Lyons; William S Kremen Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Megan S Barker; Masood Manoochehri; Sandra J Rizer; Brian S Appleby; Danielle Brushaber; Sheena I Dev; Katrina L Devick; Bradford C Dickerson; Julie A Fields; Tatiana M Foroud; Leah K Forsberg; Douglas R Galasko; Nupur Ghoshal; Neill R Graff-Radford; Murray Grossman; Hilary W Heuer; Ging-Yuek Hsiung; John Kornak; Irene Litvan; Ian R Mackenzie; Mario F Mendez; Belen Pascual; Katherine P Rankin; Katya Rascovsky; Adam M Staffaroni; Maria Carmela Tartaglia; Sandra Weintraub; Bonnie Wong; Bradley F Boeve; Adam L Boxer; Howard J Rosen; Jill Goldman; Edward D Huey; Stephanie Cosentino Journal: Cortex Date: 2021-03-19 Impact factor: 4.644
Authors: Mario Amore Cecchini; Mônica Sanches Yassuda; Valéria Santoro Bahia; Leonardo Cruz de Souza; Henrique Cerqueira Guimarães; Paulo Caramelli; Maria Teresa Carthery-Goulart; Flávia Patrocínio; Maria Paula Foss; Vitor Tumas; Thaís Bento Lima-Silva; Sônia Maria Dozzi Brucki; Ricardo Nitrini; Sergio Della Sala; Mario A Parra Journal: J Neurol Date: 2017-09-11 Impact factor: 4.849
Authors: Laura A Rabin; Crystal G Guayara-Quinn; Caroline O Nester; Liam Ellis; Nadia Paré Journal: Neuropsychol Dev Cogn B Aging Neuropsychol Cogn Date: 2021-02-23